Thiazovivin

CAS: 1226056-71-8 F: C15H13N5OS W: 311.36

Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Thiazovivin is a potent ROCK inhibitor[1].
Invitro	Thiazovivin (GMP) (0.5 μM, at 1 day) promotes rapid and efficient reprogramming of mouse tail tip and embryonic fibroblasts into iPSCs[1].Thiazovivin (GMP) enhances the efficiency in reprograming endometrial adult stromal cells to iPSCs[2].Thiazovivin (GMP) (2 μM) induces iPSCs and induced neural stem cells (iNSCs) from human urine cells (UCs)[3].Thiazovivin (GMP) (2 μM, for the first 24 h) improves growth rate of hiPSCs[4].Thiazovivin (GMP) (0.5 μM) together with SB431542 and PD0325901 promotes iPSC reprogramming by regulating cell-cell interactions[5].
Name	Thiazovivin
CAS	1226056-71-8
Formula	C15H13N5OS
Molar Mass	311.36
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Park HS, et al. Generation of induced pluripotent stem cells without genetic defects by small molecules. Biomaterials. 2015 Jan;39:47-58. [2]. Mohseni R, et al. Reprogramming of endometrial adult stromal cells in the presence of a ROCK inhibitor, thiazovivin, could obtain more efficient iPSCs. Cell Biol Int. 2015 May;39(5):515-8. [3]. Cheng L, et al. Generation of Urine Cell-Derived Non-integrative Human iPSCs and iNSCs: A Step-by-Step Optimized Protocol. Front Mol Neurosci. 2017 Oct 30;10:348. [4]. Kuo HH, et al. Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Reports. 2020 Feb 11;14(2):256-270. [5]. Lin T, et al. A chemical platform for improved induction of human iPSCs. Nat Methods. 2009 Nov;6(11):805-8.